EU begins review of Bavarian Nordic's vaccine for monkeypox

1 minute read

An employee of the vaccine company Bavarian Nordic works in a laboratory of the company in Martinsried near Munich, Germany, May 24, 2022. The company, headquartered in Denmark, is the only one in the world to have approval for a smallpox vaccine called Jynneos in the U.S. and Imvanex in Europe, which is also effective against monkeypox. REUTERS/Lukas Barth/File Photo

Register now for FREE unlimited access to Reuters.com

June 28 (Reuters) - The European Union's drug regulator said on Tuesday it has started a review to extend the use of Bavarian Nordic's (BAVA.CO) smallpox vaccine to prevent monkeypox disease as well.

The Danish biotech's Imvanex vaccine is approved for smallpox in Europe, but has been provided for off-label use to treat monkeypox cases.

More than 3,400 confirmed monkeypox cases and one death were reported to the World Health Organization till last week, with a majority of them from Europe. read more

Register now for FREE unlimited access to Reuters.com

Bavarian Nordic's shot has already been cleared for both smallpox and monkeypox in the United States, where it is called Jynneos.

The decision to start the EU review is based on results from laboratory studies suggesting that the vaccine triggers the production of antibodies that target the monkeypox virus, the European Medicines Agency said.

The regulator also advised importing the vaccine from the United States to supplement tight supply in Europe as infection rates rise across the bloc.

Earlier in June, the European Union signed an agreement with Bavarian Nordic for the supply of about 110,000 doses of its vaccines against monkeypox.

Register now for FREE unlimited access to Reuters.com
Reporting by Mrinalika Roy in Bengaluru; Editing by Devika Syamnath

Our Standards: The Thomson Reuters Trust Principles.